The core of the concern raised by APIC and SHEA is operational rather than abstract. Infection preventionists and healthcare epidemiologists working on the front lines of American medicine depend daily on the CDC’s science, surveillance systems, and guidance documents to make decisions that protect both patients and healthcare personnel. When a hospital investigates a cluster of healthcare-associated infections, when a nursing home must respond to an outbreak of a respiratory pathogen, or when an outpatient clinic needs to update its vaccination protocols, the technical foundation for those decisions typically originates at the federal agency. According to the joint statement, that foundation is visibly weakening: guidance is slower to arrive, technical assistance is harder to reach, and scientific expertise is thinner precisely when it is most needed.

The timing of the reported workforce losses amplifies the risk. Healthcare facilities are entering the respiratory virus season without updated federal vaccine recommendations, a gap that leaves infection prevention teams without the authoritative national benchmarks they have historically relied upon to standardize immunization practices across institutions. At the same time, facilities are preparing for potential measles exposures, a disease that demands rapid identification, isolation, and contact tracing protocols grounded in current epidemiological evidence. The organizations also point to the monitoring of imported threats such as Ebola, which requires sustained laboratory capacity, surveillance infrastructure, and rapid communication channels between federal scientists and local practitioners. Each of these scenarios depends on a functioning national public health partner, and each becomes more hazardous when that partner is operating with a substantially reduced workforce.

Infection prevention is a discipline built on the rapid translation of scientific evidence into bedside practice. Infection preventionists are the specialists who design and enforce the protocols that prevent healthcare-associated infections, which affect millions of patients worldwide each year and represent one of the most common adverse events in medical care. Healthcare epidemiologists complement this work by applying epidemiological methods to detect outbreaks, evaluate antimicrobial resistance patterns, and assess the effectiveness of preventive interventions within healthcare settings. Both professions operate within a distributed network in which local expertise is amplified by national coordination. The CDC functions as the hub of that network, synthesizing data from thousands of facilities, issuing evidence-based recommendations, and providing the laboratory and technical infrastructure that individual institutions cannot replicate on their own.

APIC President Kathy Ward, a registered nurse with advanced credentials in infection control, framed the relationship between frontline practitioners and the federal agency as a partnership that is now under strain. In the statement, she emphasized that infection preventionists safeguard the nation’s healthcare system against healthcare-associated infections and that the profession depends on the CDC to provide timely, evidence-based guidance. She warned that the losses described in the reporting put that partnership, and patient safety itself, at risk. Her comments reflect a practical reality: when federal guidance is delayed or unavailable, individual facilities must improvise, and improvisation in infection control can lead to inconsistent practices, gaps in protection, and ultimately preventable infections.

SHEA President Lisa Maragakis, a physician and epidemiologist, directed her warning toward a longer-term consequence of workforce erosion. In the statement, she observed that healthcare epidemiology is built on sound science and trusted data, and she characterized the CDC’s scientific independence and expert workforce as national assets that cannot be rebuilt overnight once they are lost. This point carries particular technical weight. The scientists who staff the agency’s emerging infectious disease and respiratory disease centers accumulate institutional knowledge, methodological expertise, and operational experience that are not easily transferred or replaced. Experienced federal scientists develop the capacity to recognize early signals of emerging threats, to design surveillance systems that capture meaningful data, and to communicate complex findings to practitioners who need actionable guidance. When such experts depart, their institutional memory departs with them, and rebuilding that capacity requires years of recruitment, training, and mentorship.

The downstream effects of a weakened CDC do not remain contained within the agency. As APIC and SHEA describe it, when the national partner is weakened, the burden shifts to already stretched healthcare facilities and to state and local health departments, many of which have faced their own staffing and funding challenges in recent years. State and local public health agencies depend on federal technical assistance, laboratory confirmation capabilities, and coordinated data systems to carry out their mandates. When federal capacity contracts, these agencies absorb responsibilities they may lack the resources to fulfill, and the resulting gaps propagate outward to patients and communities, who ultimately bear the consequences in the form of increased exposure to preventable infections and slower responses to outbreaks.

In response to the situation, the two organizations have issued a three-part call to action directed at Congress and the Administration. First, they urge the restoration and sustained support of CDC staffing in infectious disease programs, healthcare quality promotion, and laboratory operations, the specific divisions whose expertise underpins infection prevention practice nationwide. Second, they call for the protection of the agency’s scientific independence, reflecting a concern that political interference in scientific processes would further undermine the credibility and reliability of federal guidance. Third, they demand that funds appropriated for state and local public health partners be distributed promptly, ensuring that the frontline agencies responsible for local outbreak response receive the resources that Congress has already allocated. Together, these recommendations address the workforce, the institutional safeguards, and the funding pipelines that the organizations view as the essential infrastructure of national infection prevention capability.

The statement also situates the current moment within a broader understanding of how healthcare safety is produced. The prevention of healthcare-associated infections is not achieved by any single institution acting alone; it is the product of a layered system in which federal science, state and local public health infrastructure, and frontline clinical expertise reinforce one another. Surveillance data collected by the CDC inform the guidelines that infection preventionists implement in their facilities, and the observations of those frontline practitioners in turn feed back into national evidence. Disruption at any layer degrades the entire system, but disruption at the federal layer is particularly consequential because it affects every facility simultaneously. The organizations’ warning suggests that the reported loss of nearly a third of the agency’s workforce represents precisely such a systemic disruption, one whose effects are already observable in delayed guidance and reduced access to technical assistance.

As respiratory virus season proceeds and as facilities continue to prepare for measles exposures and monitor imported threats, the concerns articulated by APIC and SHEA are likely to frame an ongoing policy debate about the nation’s public health readiness. The organizations’ message is that the expertise housed within the CDC constitutes a form of national infrastructure comparable in importance to physical systems, and that its loss carries consequences measured not in budget figures but in patient outcomes. Their statement serves as both a diagnosis of the current strain on the infection prevention community and a formal request to federal policymakers to restore the scientific capacity on which American healthcare safety has long depended. Whether that request translates into legislative and administrative action remains to be seen, but the two societies have made clear that, in their assessment, the window for protecting this critical national asset is narrowing.

Subject of Research: Impact of CDC workforce reductions on infection prevention and healthcare epidemiology

Article Title: APIC and SHEA Statement on reported erosion of CDC capacity

Article References: APIC and SHEA Statement on reported erosion of CDC capacity. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CDC, APIC, SHEA, infection prevention, healthcare epidemiology, public health workforce, healthcare-associated infections, respiratory virus season, vaccine recommendations, measles, Ebola, health policy

The core financial argument is striking. According to the authors’ estimates, a representative 200-bed community hospital that implements all five interventions could generate approximately $2.5 million to $2.8 million in annual laboratory and clinical savings. Beyond those direct savings, hospitals that improve their baseline performance on quality metrics could reduce penalties under the Centers for Medicare and Medicaid Services Hospital-Acquired Condition program by an estimated $200,000 to $600,000. The interventions may also improve publicly reported healthcare-associated infection metrics and strengthen hospital reputation, benefits that carry real competitive weight in an era when patients and payers increasingly scrutinize quality data.

Diagnostic stewardship, at its heart, is about ensuring the right test is ordered for the right patient at the right time—and that results are interpreted appropriately once they return. It is a discipline aimed at eliminating the cascade of harm that follows unnecessary or poorly targeted testing: false-positive results that trigger unneeded antibiotics, incidental findings that lead to invasive follow-up procedures, prolonged hospital stays, and wasted laboratory resources. Unlike efforts to restrict care, diagnostic stewardship refines decision-making at the moment a test is considered, making it an attractive target for both clinicians and administrators seeking measurable improvement.

The guide examines five common opportunities for improvement that recur across hospital settings. The first is optimizing testing for Clostridioides difficile, the bacterium responsible for severe, sometimes life-threatening diarrheal infections in healthcare settings. Because molecular assays can detect the organism in patients who are merely colonized rather than truly infected, testing unformed stools indiscriminately inflates infection rates and drives unnecessary treatment and isolation. The second and third targets are optimizing urine culture use and de-implementing unnecessary procalcitonin testing. Urine cultures ordered in patients without symptoms frequently reveal asymptomatic bacteriuria, a common finding that is often inappropriately treated with antibiotics, fueling resistance and adverse drug events. Procalcitonin, a biomarker sometimes used to guide antibiotic decisions, is frequently ordered in situations where the result will not change management, consuming resources without benefiting patients.

The remaining two interventions address the explosive growth of multiplex diagnostics. Optimizing respiratory pathogen panel use tackles panels that test for dozens of viruses and bacteria simultaneously in patients whose care would change little based on the full results, encouraging clinicians instead to select narrower panels or targeted tests matched to the clinical question. Optimizing blood culture use rounds out the list, addressing the widespread practice of drawing blood cultures from patients with low pretest probability of bloodstream infection or from indwelling lines where contamination is likely. Each unnecessary culture carries costs in laboratory processing, false-positive contamination that prompts additional testing and antibiotics, and extended lengths of stay when ambiguous results are reflexively treated.

For each of the five interventions, the authors lay out implementation strategies, projected financial impact, and practical examples that hospitals can adapt to their own circumstances. The financial models are designed to translate clinical improvements into the language of hospital administration: avoided laboratory costs, reduced antibiotic expenditures, shortened lengths of stay, and improved quality measure performance. That translation matters, because diagnostic stewardship programs typically require upfront investment in education, electronic health record modifications, and personnel time, and program champions must often justify those costs to budget-conscious executives before any savings are realized.

Senior author Sarah E. Turbett, MD, framed the resource as a bridge between clinical value and operational performance. Healthcare leaders know that every investment must improve both patient care and operational performance, she noted, and this framework helps hospitals evaluate and implement diagnostic stewardship in ways that improve clinical outcomes, strengthen quality metrics, and demonstrate measurable value. The emphasis on measurable value reflects a growing recognition that programs perceived as purely clinical initiatives often struggle to survive budget cycles, while those with robust business cases secure sustained institutional support.

The publication arrives at a moment when diagnostic excellence is receiving increasing national attention. The Centers for Disease Control and Prevention’s Core Elements of Hospital Diagnostic Excellence identifies diagnostic stewardship as a key strategy for improving diagnosis while advancing healthcare quality, safety, and value-based care. By aligning its guidance with that national framework, SHEA positions diagnostic stewardship as a central pillar of hospital quality improvement rather than a niche laboratory concern, giving infection preventionists, laboratory directors, and antimicrobial stewardship teams a shared vocabulary for engaging executive leadership.

The guide was developed by SHEA’s Diagnostic Stewardship Special Interest Group, a body convened specifically to advance this field, and it is aimed at a broad professional audience: healthcare executives, laboratory leaders, infection prevention professionals, antimicrobial stewardship teams, and frontline clinicians. Each of these groups plays a distinct role in making diagnostic stewardship succeed. Executives control the resources, laboratory leaders understand the technical nuances of test performance and utilization, infection prevention teams track the downstream effects on healthcare-associated infection metrics, stewardship programs connect testing behavior to antibiotic use, and clinicians ultimately decide which tests to order and how to interpret them.

For hospitals weighing whether to act, the combined figures offer a compelling bottom line. Direct savings of $2.5 million to $2.8 million annually, plus up to $600,000 in avoided CMS penalties, represent the kind of return that few quality initiatives can match—achieved largely by doing fewer, better-targeted tests rather than buying new technology. The authors emphasize that actual results will vary with each hospital’s baseline performance, patient population, and existing stewardship infrastructure, which is precisely why the guide insists on institution-specific business cases rather than one-size-fits-all projections. What the resource makes clear is that diagnostic stewardship has matured from a conceptual ideal into an operational discipline with documented strategies, modeled financial impact, and demonstrated potential to improve patient care, healthcare quality, and hospital finances simultaneously. As pressure mounts to deliver safer, higher-value care, the guide suggests that one of the most powerful tools available to hospitals may be simply ordering the right test, for the right patient, at the right time.

Subject of Research: Building hospital business cases for diagnostic stewardship interventions to improve patient care and reduce costs

Article Title: SHEA publishes resource to help hospitals build the business case for diagnostic stewardship

Article References: SHEA publishes resource to help hospitals build the business case for diagnostic stewardship. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: diagnostic stewardship, SHEA, hospital savings, Clostridioides difficile testing, urine culture, procalcitonin, respiratory pathogen panels, blood culture, antimicrobial stewardship, CMS penalties, healthcare quality, infection prevention